Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation

被引:73
作者
Balijepalli, S
Boyd, MR
Ravindranath, V
机构
[1] Natl Inst Mental Hlth & Neurosci, Dept Neurochem, Bangalore 560029, Karnataka, India
[2] NCI, Lab Drug Discovery Res & Dev, Dev Therapeut Program, FCRDC, Frederick, MD 21702 USA
关键词
haloperidol; complex I; brain; glutathione; protein thiol; neuroleptic;
D O I
10.1016/S0028-3908(98)00215-9
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We have examined the: effects of a variety of classical and atypical neuroleptic drugs on mitochondrial NADH ubiquinone oxido-reductase (complex I) activity. Sagittal slices of mouse brain incubated in vitro with haloperidol (10 nM) showed time- and concentration-dependent inhibition of complex I. Similar concentrations of the pyridinium metabolite of haloperidol (HPP+) failed to inhibit complex I activity in this model; indeed, comparable inhibition was obtained only at a 10 000-fold higher concentration of HPP+ (100 mu M). Treatment of brain slices with haloperidol resulted in a loss of glutathione (GSH), while pretreatment of slices with GSH and alpha-lipoic acid abolished haloperidol-induced loss of complex I activity. Incubation of mitochondria from haloperidol treated brain slices with the thiol reductant, dithiothreitol, completely regenerated complex I activity demonstrating thiol oxidation as a feasible mechanism of inhibition. In a comparison of different neuroleptic drugs, haloperidol was the most potent inhibitor of complex I, followed by chlorpromazine, fluphenazine and risperidone while the atypical neuroleptic, clozapine (100 mu M) did not inhibit complex I activity in mouse brain slices. The present studies support the view that classical neuroleptics such as haloperidol inhibit mitochondrial complex I through oxidative modification of the enzyme complex. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:567 / 577
页数:11
相关论文
共 36 条
[1]   EVIDENCE FOR DIFFERENT STATES OF THE DOPAMINE D1 RECEPTOR - CLOZAPINE AND FLUPERLAPINE MAY PREFERENTIALLY LABEL AN ADENYLATE CYCLASE-COUPLED STATE OF THE D1-RECEPTOR [J].
ANDERSEN, PH ;
BRAESTRUP, C .
JOURNAL OF NEUROCHEMISTRY, 1986, 47 (06) :1822-1831
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]   TARDIVE DYSTONIA - LATE-ONSET AND PERSISTENT DYSTONIA CAUSED BY ANTI-PSYCHOTIC DRUGS [J].
BURKE, RE ;
FAHN, S ;
JANKOVIC, J ;
MARSDEN, CD ;
LANG, AE ;
GOLLOMP, S ;
ILSON, J .
NEUROLOGY, 1982, 32 (12) :1335-1346
[4]  
CASEY DE, 1991, CURR OPIN PSYCHIATR, V4, P86
[5]   SIMILARITY OF CLOZAPINE AND SCH 23390 IN RESERPINIZED RATS SUGGESTS A COMMON MECHANISM OF ACTION [J].
CHIPKIN, RE ;
LATRANYI, MB .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 136 (03) :371-375
[6]   DEPRENYL SUPPRESSES THE OXIDANT STRESS ASSOCIATED WITH INCREASED DOPAMINE TURNOVER [J].
COHEN, G ;
SPINA, MB .
ANNALS OF NEUROLOGY, 1989, 26 (05) :689-690
[7]   DOPAMINE RECEPTOR-BINDING PREDICTS CLINICAL AND PHARMACOLOGICAL POTENCIES OF ANTI-SCHIZOPHRENIC DRUGS [J].
CREESE, I ;
BURT, DR ;
SNYDER, SH .
SCIENCE, 1976, 192 (4238) :481-483
[8]  
GIBSON SL, 1983, CANCER RES, V43, P4191
[9]   THE PHENOTHIAZINETRANQUILIZERS - BIOCHEMICAL AND BIOPHYSICAL ACTIONS [J].
GUTH, PS ;
SPIRTES, MA .
INTERNATIONAL REVIEW OF NEUROBIOLOGY, 1964, 7 :231-278
[10]  
Hatefi Y, 1978, Methods Enzymol, V53, P21